Form 4: Nautilus Biotechnology CFO Boosts Stake with Significant Common Stock Purchase

Anna Mowry, CFO and Treasurer of Nautilus Biotechnology, Inc., purchased 15,000 shares of common stock, signaling increased insider confidence.

Summary

• Anna Mowry, the Chief Financial Officer and Treasurer of Nautilus Biotechnology, Inc. (NAUT), acquired 15,000 shares of the company's common stock.
• The transaction took place on May 29, 2025, with the shares purchased at a weighted average price of $0.7659 per share.
• The purchase price range for these shares was from $0.7489 to $0.7662.
• Following this acquisition, Ms. Mowry's total beneficial ownership in Nautilus Biotechnology, Inc. stands at 83,000 shares.
• The total beneficial ownership includes shares previously acquired through the Issuer's 2021 Employee Stock Purchase Plan (ESPP) on multiple dates: 1,250 shares on December 1, 2022; 1,250 shares on June 1, 2023; 1,250 shares on December 1, 2023; 2,500 shares on May 31, 2024; 2,500 shares on November 29, 2024; and 2,500 shares on May 30, 2025.

Sentiment

Score: 7

Explanation: The purchase of shares by a key executive like the CFO is generally a positive signal, indicating confidence in the company's future. While the low share price at which the purchase occurred might suggest a depressed valuation, the insider's willingness to invest personal capital is a strong vote of confidence.

Positives

• The purchase of 15,000 shares by the CFO and Treasurer, Anna Mowry, indicates strong insider confidence in Nautilus Biotechnology's future prospects and valuation.
• Increased insider ownership aligns management's financial interests more closely with those of public shareholders, potentially fostering better corporate governance and decision-making.

Negatives

• The relatively low purchase price of $0.7659 per share could suggest that the stock is currently trading at a depressed valuation, potentially reflecting underlying challenges or market skepticism.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding Nautilus Biotechnology's future operational or financial outlook.

Management Comments

• The document does not contain direct quotes or paraphrased statements from company management, beyond the factual reporting of the transaction.

Industry Context

Insider purchases, particularly by a Chief Financial Officer, are often interpreted by the market as a positive signal, suggesting that management believes the company's stock is undervalued or that significant positive developments are anticipated. In the biotechnology sector, such confidence can be particularly impactful given the long development cycles and inherent risks, indicating belief in the company's technology or pipeline despite market volatility.

Related Party Transactions

• The purchase of 15,000 shares of common stock by Anna Mowry, the CFO and Treasurer, from the open market, constitutes a disclosed related party transaction.

Stakeholder Impact

• Shareholders: The insider purchase may be viewed positively, potentially boosting investor confidence and signaling management's belief in the company's intrinsic value.
• Employees: The CFO's personal investment could reinforce confidence among employees regarding the company's stability and future prospects.

Key Dates

Recommendation

Keywords

Nautilus Biotechnology, NAUT, Form 4, Insider Trading, Stock Purchase, Anna Mowry, CFO, Biotechnology, SEC Filing, Employee Stock Purchase Plan